iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.

iRhythm Technologies Launches Zio Monitoring Across Europe

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio monitor and Zio long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union's CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1.

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern Time Wells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern Time Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 2:00 pm Eastern time Those interested in listening to the presentations may do so by accessing the live and archived webcast of the events on the “Events & Presentations” section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease.

iRhythm Technologies to Participate in Upcoming Investor Conferences in September

iRhythm Technologies (IRTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About iRhythm Technologies (IRTC) Rating Upgrade to Buy

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q1 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - President and CEO Brice Bobzien - Chief Financial Officer Daniel Wilson - EVP of Corporate Development and Investor Relations Conference Call Participants Margaret Andrew - William Blair Allen Gong - JPMorgan Marie Thibault - BTIG LLC David Rescott - Baird Nathan Treybeck - Wells Fargo Joanne Wuensch - Citigroup Mike Polark - Wolfe Research Ravi Misra - Truist David Saxon - Needham & Company Suraj Kalia - Oppenheimer Operator Hello all, and welcome to iRhythm Technologies Second Quarter 2024 Earnings Conference Call. My name is Lydia and I'll be your operator today.

iRhythm Technologies, Inc. (IRTC) Q2 2024 Earnings Call Transcript

IRhythm Technologies (IRTC) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.61 per share a year ago.

IRhythm Technologies (IRTC) Reports Q2 Loss, Tops Revenue Estimates

SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc . (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm's current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, and he will continue to serve the Company in an advisory capacity into 2025 following the succession to ensure a smooth transition.

iRhythm Technologies Announces Chief Financial Officer Transition

Abbott Labs

Edwards Lifesciences

Glaukos

Johnson & Johnson

Inari Medical

SI-BONE Inc

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.

7 Leading MedTech Stocks for Next-Gen Health Solutions

ABB Ltd

Boston Scientific

iRobot

Intuitive Surgical

UiPath

Teradyne

Robotics stocks are a good investment as the industry is rapidly progressing.  Robotics stocks have great potential to increase their revenues in the future due to the increased usage of robots in different industries due to technological developments.

7 Robotics Stocks That Could Grow Your Wealth

GE HealthCare Technologies Inc

Masimo

After taking a backseat in the first half, the healthcare sector is finally coming to life. The rising odds of a Trump presidency have improved prospects for the industry, validating the case for increasing positions in healthcare stocks to buy now.

3 Healthcare Stocks to Buy Now: Q3 Edition

SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Skyworks Solutions

Bread Financial Holdings Inc

Ocular Therapeutix

TransUnion

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings.

iRhythm Technologies Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Truist Securities MedTech Conference.

iRhythm Technologies to Present at the 2024 Truist Securities MedTech Conference

SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming William Blair 44th Annual Growth Stock Conference.

iRhythm Technologies to Present at the William Blair 44th Annual Growth Stock Conference

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, IR Quentin Blackford - President and CEO Brice Bobzien - CFO Conference Call Participants Allen Gong - JPMorgan Malgorzata Kaczor - William Blair Richard Newitter - Truist Marie Thibault - BTIG Joanne Wuensch - Citibank Kallum Titchmarsh - Morgan Stanley Nathan Treybeck - Wells Fargo David Rescott - Baird Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Operator Hello, and welcome to the iRhythm Technologies, Inc. Q1 2024 Earnings Conference Call. My name is Terry, and I will be the conference operator today.

iRhythm Technologies, Inc. (IRTC) Q1 2024 Earnings Call Transcript

SAN FRANCISCO, April 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2024 after the close of trading on Thursday, May 2, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your iRhythm Technologies, Inc. (NASDAQ:IRTC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/irhythm-technologies-lawsuit-submission-form?prid=74832&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on iRhythm Technologies, Inc.(IRTC) should contact Levi & Korsinsky about pending Class Action - IRTC

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your iRhythm Technologies, Inc. (NASDAQ:IRTC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/irhythm-technologies-lawsuit-submission-form?prid=74773&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies iRhythm Technologies, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - IRTC

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your iRhythm Technologies, Inc. (NASDAQ:IRTC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/irhythm-technologies-lawsuit-submission-form?prid=74748&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against iRhythm Technologies, Inc. (IRTC) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of iRhythm Technologies, Inc. (NASDAQ: IRTC) between January 11, 2022 and May 30, 2023, both dates inclusive (the “Class Period”), of the important April 8, 2024 lead plaintiff deadline. SO WHAT: If you purchased iRhythm common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen.

IRTC DEADLINE TODAY: ROSEN, A RANKED AND LEADING FIRM, Encourages iRhythm Technologies, Inc. Investors to Secure Counsel Before Important April 8 Deadline in Securities Class Action – IRTC

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your iRhythm Technologies, Inc. (NASDAQ:IRTC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/irhythm-technologies-lawsuit-submission-form?prid=74671&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by April 8, 2024 Deadline to Join Class Action Against iRhythm Technologies, Inc. (IRTC)

LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against iRhythm Technologies, Inc. ("iRhythm," or "the Company") (NASDAQ:IRTC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 11, 2022 and May 30, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 8, 2024.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in iRhythm Technologies, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , April 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in iRhythm Technologies, Inc. ("iRhythm Technologies" or the "Company") (NASDAQ: IRTC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of iRhythm Technologies investors who were adversely affected by alleged securities fraud between January 11, 2022 and May 30, 2023.

Shareholders that lost money on iRhythm Technologies, Inc.(IRTC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for iRhythm Technologies Stock (IRTC)